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Background: Astragalus polysaccharides (APS) are active constituents of Astragalus membranaceus. They have
been widely studied, especially with respect to their immunopotentiating properties, their ability to counteract the
side effects of chemotherapeutic drugs, and their anticancer properties. However, the mechanism by which APS
inhibit cancer and the issue of whether that mechanism involves the reversal of multidrug resistance (MDR) is not
completely clear. The present paper describes an investigation of the effects of APS on P-glycoprotein function
and expression in H22 hepatoma cell lines resistant to Adriamycin (H22/ADM).
Methods: H22/ADM cell lines were treated with different concentrations of APS and/or the most common
chemotherapy drugs, such as Cyclophosphamid, Adriamycin, 5-Fluorouracil, Cisplatin, Etoposide, and Vincristine.
Chemotherapeutic drug sensitivity, P-glycoprotein function and expression, and MDR1 mRNA expression were
detected using MTT assay, flow cytometry, Western blotting, and quantitative RT-PCR.
Results: When used alone, APS had no anti-tumor activity in H22/ADM cells in vitro. However, it can increase
the cytotoxicity of certain chemotherapy drugs, such as Cyclophosphamid, Adriamycin, 5-Fluorouracil, Cisplatin,
Etoposide, and Vincristine, in H22/ADM cells. It acts in a dose-dependent manner. Compared to a blank control
group, APS increased intracellular Rhodamine-123 retention and decreased P-glycoprotein efflux function in a
dose-dependent manner. These factors were assessed 24 h, 48 h, and 72 h after administration. APS down
regulated P-glycoprotein and MDR1 mRNA expression in a concentration-dependent manner within a final range
of 0.8–500 mg/L and in a time-dependent manner from 24–72 h.
Conclusion: APS can enhance the chemosensitivity of H22/ADM cells. This may involve the downregulation of
MDR1 mRNA expression, inhibition of P-GP efflux pump function, or both, which would decrease the expression
of the MDR1 protein.
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Cancer is as a major public health problem worldwide
[1]. The World Health Organization predicts that, by
2030, an estimated 21.4 million new cases of cancer and
13.2 million cancer deaths will occur annually [2]. Sur-
gery, radiation, chemotherapy, and endocrine therapy
are the standard cancer therapies [3]. For advanced* Correspondence: lihuande1953@126.com
1Clinical Pharmacy and Pharmacology Research Institute, The Second
Xiangya Hospital, Central South University, 139 Renmin Middle Road,
Changsha, Hunan 410011, China
Full list of author information is available at the end of the article
© 2012 Tian et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortumors, chemotherapy is the treatment of choice.
Although these drugs are effective, they are associated
with severe adverse events and drug resistance, espe-
cially multidrug resistance (MDR) [4].
Drug resistance involves many mechanisms. MDR is
the leading cause of treatment failure in cancer therapy.
Once MDR emerges, chemotherapy becomes ineffective.
High doses of drugs are required to overcome resistance,
but this has toxic effects in the patient and can increase
resistance further [5]. One of the underlying mechanisms
of MDR is cellular overproduction of P-glycoprotein
(P- GP), which acts as an efflux pump for various antic-
ancer drugs. P-GP is encoded by the MDR1 gene. P-GP. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cumventing MDR. One strategy is to co-administer
efflux pump inhibitors, but such reversal agents might
increase the side effects of chemotherapy by blocking
physiological anticancer drug efflux from normal cells.
Although many efforts to overcome MDR have been
made using first- and second-generation reversal agents,
including drugs already in clinical use for other condi-
tions (e.g. verapamil, cyclosporine A, quinidine) and ana-
logues of first-generation drugs (e.g. dexverapamil,
valspodar, cinchonine), few significant advances have
been made. Clinical trials with third generation modula-
tors (e.g. biricodar, zosuquidar, and laniquidar) specific-
ally developed for MDR reversal are ongoing. The
results, however, are not encouraging and it may be that
no perfect reverser currently exists [6].
Traditional Chinese medicine (TCM) and herbal medi-
cines in particular have been used in the treatment of
cancer for thousands of years in China, Japan, South
Korea, and other Asian countries. These medicines are
widely accepted as current forms of complementary and
alternative cancer treatments in the United States and
Europe [7,8]. Experiments have shown that TCM plays an
anticancer role by inducing apoptosis and differentiation,
enhancing immune response, inhibiting angiogenesis, and
reversing MDR [9]. TCM has great advantages in terms
of increasing the sensitivity of chemo-therapeutics, redu-
cing the side effects and complications associated with
chemotherapy, and improving both patient quality of life
and survival time [10]. In the search for new cancer ther-
apeutics with low toxicity and few side effects, TCM
shows promise [11].
The dried root of Astragalus membranaceus has a long
history of medicinal use in TCM. It is traditionally pre-
pared as a tonic that can improve the functioning of the
lungs, adrenal glands, and the gastrointestinal tract, in-
crease metabolism, promote healing, and reduce fatigue
[12]. The active pharmacological constituents of Astrag-
alus membranaceus include various polysaccharides,
saponins, flavonoids, and L-arginine and L-canavanine
[13,14]. Among these, Astragalus polysaccharides (APS)
has been most widely studied, mainly with respect to
its immunopotentiating properties, its ability to counter-
act the side effects of chemotherapeutic drugs, and its
anticancer activity [12,14-24]. However, the anti-cancer
mechanism of APS and the issue of whether or not
it involves the reversal of multi-drug resistance are
not completely clear. Reports indicate that Astragalus
membranaceus compound preparations “Changweiqing”
and “Jiexinkang” can reverse multidrug resistance and
that “preventing recurrence formula for UC” can inhibit
the expression of P-gp in colon tissue [25-27]. APS is
the main active ingredient of Astragalus membranaceus,
and it is worthy of further investigation.The present study focused on investigating the effects
and relevant mechanisms of APS on P-GP function and




APS (20000–60000 mol/L) was purchased from Shanxi
Undersun Biomedtech Co. Ltd.). Cyclophosphamid
(MTX), Adriamycin (ADM), 5-fluorouracil (5-Fu),
cisplatin (DDP), etoposide (VP-16), vincristine (VCR),
verapamil (VER), and rifampicin (RFP) were purchased
from the National Institutes for Food and Drug Control).
A two-step immunohistochemistry detection kit PV-
9000; Rhodamine123 (Rh-123); TaKaRaRNA PCRI Kit
(AMV) Ver3.0; and TRIZOL reagent were purchased
from SIGMA Corporation. Goat anti-mouse IgG and
fluorescein-affinity pure goat anti-rabbit IgG were pur-
chased from Jackson ImmunoResearch Laboratories.
Oligonucleotides and reagents for PCR assay were pur-
chased from SIGMA Corporation.
Cell lines and culture conditions
H22/ADM cell lines purchased from Beijing Cowin Biotech
Co. Ltd were incubated in medium containing 1 mg/L
ADM to maintain its resistant characteristics. We kept
H22/ADM cells in medium without ADM for 2 weeks
before using these cells. The cells were cultured at 37°C in
5% CO2 with 100% humidity in RPMI1640 medium (Gibco/
BRL, Bethesda, MD, U.S.) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Sijiqing, Hangzhou,
China), 100 U/ml penicillin, 100 U/ml streptomycin.
MTT assay for detection of H22/ADM cell proliferation
For cell growth and viability assays, 5 × 104/ml H22/
ADM cells were plated into 96 well cell culture plates
(Costar, Charlotte, NC, U.S.) at 190 μl per well. After
24 h of incubation, they were divided into ten groups of
six parallel wells each. One group contained 200 μl cul-
ture medium and served as a negative control group.
Another group contained 10 μl 0.9% normal saline (NS)
and served as a solvent control group. Three more groups
contained DDP (0.1 mg/L, 1.0 mg/L, and 10 mg/L) and
served as positive control groups. The remaining five
experimental groups received different final concentra-
tions of APS (0.8 mg/L, 4 mg/L, 20 mg/L, 100 mg/L, and
500 mg/L). After incubation for 24 h, 10 μl MTT solution
(5 mg/ml) was added to each well at 37°C in the dark and
allowed to incubate for at least 4 h. Formazan crystals
were solubilized in 150 μl dimethyl sulfoxide (DMSO) in
every well, gently swinging 10 min. The optical density
(OD) was read at 540 nm and 490 nm using a plate
reader (Model 550; Bio-Rad, Tokyo, Japan). Relative
inhibition of cell growth was expressed as follows:
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[28]. Half inhibitory concentration (IC50) is calculated by
linear regression equation. Each assay was repeated three
times.
MTT assay of the sensitivity of H22/ADM cells to
chemotherapeutic drugs
For cell growth and viability assays, 5× 104/ml H22/
ADM cells were plated into 96 well cell culture micro-
plates, 100 μl per well, respectively. After 6 h of incuba-
tion, the cells were divided into seven groups of six
parallel wells each. One group received 200 μl culture
medium. This served as a control group. The other
groups received 10 μl volumes of different final concen-
trations of APS (0.8 mg/L, 4 mg/L, 20 mg/L, 100 mg/L,
500 mg/L). The cells that received these quantities of
APS served as five experimental groups [29-31]. After
incubation for 24 h, the medium was discarded and
replaced with 190 μl of fresh medium per well. Then
10 μl the following concentrations of chemotherapy
drugs were added into each well: ADM (0.625 μg/ml,
1.25 μg/ml, 2.5 μg/ml, 5 μg/ml, 10 μg/ml), 5-Fu (25 μg/ml,
50 μg/ml, 100 μg/ml, 200 μg/ml, 400 μg/ml), DDP
(5 μg/ml, 10 μg/ml, 20 μg/ml, 40 μg/ml, 80 μg/ml),
VP-16 (75 μg/ml, 150 μg/ml, 300 μg/ml, 600 μg/ml,
1200 μg/ml), VCR (1.25 μg/ml, 2.5 μg/ml, 5 μg/ml,
10 μg/ml, 20 μg/ml), CTX (100 μg/ml, 200 μg/ml,
400 μg/ml, 800 μg/ml, 1600 μg/ml). After incubation
for 24 h, 10 μl MTTsolution (5mg/ml) was added into
each well at 37°C in the dark for at least 4 h. Formazan
crystals were solubilized in 150 μl DMSO in every well
with 10min of gentle mixing, and the ODwas read at a
wavelength of 540 nmand 490 nmusing a plate reader.
Relative inhibitionof cell growthwas expressed as fol-
lows: Percentage (%) = (1- [OD] test/[OD] control) ×
100% [28]. IC50 was calculated using a linear regres-
sionequation. Each assaywas repeated three times.
Rh-123 accumulation assay
The efflux activity of P-GP was determined by mea-
suring the accumulation of the fluorescent P-GP probe
Rh-123 as described by Collett A et al. [32]. In brief,
H22/ADM cells were incubated with RPMI1640 medium,
and then RPMI1640 medium (was used as a blank control
group), APS (final concentrations 0.8 mg/L, 4 mg/L,
20 mg/L, 100 mg/L, 500 mg/L), VER (P-GP antagonist,
was used as positive control) 10 μmol/L, RFP (P-GP in-
ducer, was used as positive control) 10 μmol/L for 24 h,
48 h, and 72 h before Rh-123 experiments took place.
Then cells were treated with trypsin digestion, centrifuga-
tion 700× g, 5 min, 4°C, adjusted to 1 × 106/ml of cell
suspension, and added to 1.5 ml EP tube, 0.5 ml/tube,
Rh-123 was added to cells in the final concentration of
500 μmol/L, followed by incubation at 37°C in 5% CO2incubator for 60 min. Each group included six parallel EP
tubes. After this incubation period, the cells were washed
twice (cold PBS, 4°C; centrifugation 700× g, 5 min, 4°C)
and fixed (cell fix, 0.5 ml). All samples were analyzed
using flow cytometry.
Western blot analysis
RFP (P-GP inducer) and VER (P-GP antagonist) were
used as positive controls; H22/ADM cells were used as
blank controls. Western blot analysis was performed as
described previously [33]. After treatment with VER
10 μmol/L, RFP 10 μmol/L, and APS (0.8 mg/L, 4 mg/L,
20 mg/L, 100 mg/L, 500 mg/L), cells were incubated for
24 h, 48 h, or 72 h. Cells were washed twice with ice-
cold PBS and total cell lysates were collected in sodium
dodecyl sulfate (SDS) sample buffer (50 mM Tris–HCl,
pH 6.8, 100 mM dithiothreitol (DTT), 2% SDS, 0.1%
bromophenol blue, 10% glycerol). Cell lysates containing
equal amounts of protein were separated by SDS-
polyacrylamide gel electrophoresis (PAGE) and trans-
ferred to polyvinylidine difluoride membranes. After
blocking in 5% non-fat milk in Tris-buffered saline with
0.1% Tween 20 (pH 7.6), membranes were incubated
with the appropriate primary antibodies (goat anti-
mouse IgG) at 4°C, overnight, and exposed to the appro-
priate secondary antibody (goat anti-rabbit IgG) for 3 h
at 37°C. Immunoreactive proteins were visualized using
the enhanced chemiluminescence system from Pierce
(Rockford, IL, U.S.).
Quantitative real time RT-PCR
RFP (P-GP inducer) and VER (P-GP antagonist) were
used as positive controls; H22/ADM cells were used as
blank controls. Then 5 × 104/ml H22/ADM cells were
seeded and incubated for 6 h until adherent. The cells
were treated with VER 10 μmol/L, RFP 10 μmol/L, and
APS (0.8 mg/L, 4 mg/L, 20 mg/L, 100 mg/L, 500 mg/L)
and then incubated for 24 h, 48 h, or 72 h. Each set of
exposure conditions for mRNA analysis was reproduced
and confirmed by two additional independent experi-
ments, representing biological triplicates.
MDR1 mRNA expression in H22/ADM cells was
detected by quantitative RT-PCR. Total RNA was
extracted using the TRIZOL reagent according to the
manufacturer’s instructions and reverse-transcribed to
cDNA using a Gene Amp RNA PCR kit in a DNA ther-
mal cycler (Bio-Rad). QRT-PCR was performed with
SYBR green PCR master mix in an ABI Prism 7700 real
time PCR machine (Applied Biosystems, Foster City,
CA, U.S.). The synthesized cDNA served as a template
in a (25 μL) reaction. A non-template control was
included in all experiments. Primer sequences are as
follows: P-GP, sense: 5′-TAA TGC GAC AGG AGA
TAG GCT-3′, and antisense: 5′-CCG CCA TTG ACT
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ACG GAT TTG GTC G-3′, and antisense: 5′-CGG
AAG ATG GTG ATG GGA TT-3′. QRT-PCR was per-
formed at 94°C for 4 min, followed by 40 cycles at 94°C
for 15 s, 60°C for 25 s, and 72°C for 25 s. Data were ana-
lyzed with sequence detector software (v1.9, Applied
Biosystems). The mean Ct value for duplicate measure-
ments was used to detect the expression of the target
gene with normalization to a housekeeping gene
used as an internal control (glyceraldehyde-3-phosphate
dehydrogenase GAPDH) according to the 2−ΔCt formula.
Statistical analysis
Statistical analysis for the data of cell cytotoxicity, P-GP
function and expression assays were performed on SPSS
14.0 software (v14, SPSS Inc. Chicago, IL, U.S.). The dif-
ferences in variables between the groups were analyzed
by one-way ANOVA. Real-time PCR data were analyzed
using the SDS software on the ABI PRISMW7700
sequence detection system. The confidence limit was
set at 95%. Values of P < 0.05 were considered statisti-
cally significant.
Results
Effects of APS on H22/ADM cell proliferation
Table 1 shows that the inhibition rates of APS ranged
from 1.11% to 62.40% in a concentration-dependent
manner. However, the maximum inhibition rate was
only 62.40%. The IC50 value of APS was 251.77 mg/L,
which is significantly higher than the positive control
DDP [IC50 = 0.04 mg/L] (P <0.05).
MTT assay of sensitivity of chemotherapeutic drugs
The IC50 of different concentrations of APS combined
with chemotherapeutic drugs (ADM, 5-Fu, DDP, VP-16,
VCR, or CTX) and the control group (ADM, 5-Fu, DDP,
VP-16, VCR, or CTX, when applied alone) are shown in
Figure 1. The difference between APS combined withTable 1 Impact of APS on H22/ADM cell proliferation (n =6)
Agents Concentration (mg/L) OD Value (mean± SD)
APS 0.8 0.71 ± 0.15
4 0.67 ± 0.12
20 0.61 ± 0.09
100 0.47 ± 0.04
500 0.27 ± 0.14
DDP 0.1 0.29 ± 0.02
1.0 0.21 ± 0.04
10 0.06 ± 0.03
NS 1.018 ± 1.06
DMSO 0.1 0.918 ± 0.134
★ P< 0.05, vs. DDP; ND: Not calculated; SD: Standard deviation; NS: normal saline.ADM or VCR and the control group was not significant
at APS 0.8 mg/L, but APS combined with ADM or VCR
could was found to significantly reduce the IC50 value
(P < 0.05, VS. control group) at APS concentrations of
4–500 mg/L; APS combined with 5-Fu, DDP, VP-16, or
CTX was found to significantly reduce the IC50 value
(P < 0.05, VS. control group) at APS concentrations of
0.8–500 mg/L. For APS combined with chemotherapeu-
tic drugs (ADM, 5-Fu, DDP, VCR, or CTX), the IC50
value decreased with increasing concentrations of APS
within the range of 0.8–500 mg/L, and for APS com-
bined with VP-16, the IC50 value decreased trend with
increasing concentrations of APS was not obvious.
Rh-123 accumulation assay
Rh-123 retention was measured to evaluate the P-GP
transport activity in the H22/ADM cells. The fluorescent
dye Rh-123 is a substrate of P-GP, and its cellular reten-
tion has been shown to reflect P-GP function. Rh-123
efflux was measured by counting cells in the M1 region
of the plot. The marker bar M1 was set to indicate
cells with high Rh-123 efflux. Marker bar M2 was set to
indicate the cells with low Rh-123 efflux. As shown in
Figure 2, compared with the control group, the RFP
group fluorescence curve shifted to the left, suggesting
that intracellular Rh-123 uptake decreased and P-GP
efflux increased; the fluorescence curves of the APS
(APS 0.8 mg/L, APS 4 mg/L, APS 20 mg/L, APS
100 mg/L, APS 500 mg/L) and VRE groups shifted to
the right, suggesting that intracellular Rh-123 retention
increased and P-GP efflux function decreased over the
24 h, 48 h, and 72 h time periods. However, this was
only a general trend, no shifts were obvious for the RFP
group or the 0.8 mg/L at 72 h.
Table 2 shows the intracellular fluorescence intensity
of Rh-123 accumulation in H22/ADM cells after expos-
ure to chemotherapeutic agents at 24 h, 48 h, and 72 h.
The intensity of the intracellular fluorescence of Rh-123Inhibition Rate (%) IC50 (mg/L) IC50 95%CI (mg/L)
1.11
6.69








Figure 1 IC50 of APS combined with ADM, DDP, VCR, 5-FU, VP-16 or CTX in H22/ADM cells. ★P< 0.05, vs. control group.
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group, and the intensity of the intracellular fluorescence
of Rh-123 was higher in VRE and APS groups than in
the control group at 24 h, 48 h, and 72 h. The intensity
of the intracellular fluorescence of Rh-123 increased
with increasing concentrations of APS within the range
of 0.8–500 mg/L. The difference between the APS
0.8 mg/L group and the control group was not signifi-
cant at 72 h, but other APS groups saw significant
increases (P < 0.05, VS. control group) in the intensity of
intracellular fluorescence of Rh-123 at 24 h, 48 h, and
72 h. The results show that P-GP efflux activity was
inhibited by APS.
Western blot analysis H22/ADM cell P-GP expression
The protein levels of P-GP in H22/ADM cell lines were
detected by Western blotting. As indicated in Figure 3,the level of P-GP protein was lower in the APS (APS
0.8 mg/L, APS 4 mg/L, APS 20 mg/L, APS 100 mg/L,
APS 500 mg/L) and VER groups than in the H22/ADM
group at 24 h, 48 h, and 72 h. The protein level of P-GP
was higher in the RFP group compared to H22/ADM
group at 24 h, 48 h, and 72 h time points. The same
concentration of APS affected P-GP expression in dif-
ferent ways at different times. P-GP expression was
largest at 24 h and then fell in a time-dependent
manner. Different concentrations of APS were found to
down regulate P-GP expression with increasing concen-
trations of APS in a concentration-dependent manner
in the range of 0.8–500 mg/L. These results showed
that APS could down regulate P-GP expression in a
concentration-dependent manner within the range of
0.8–500 mg/L and in a time-dependent manner from
24 h to 72 h.
Figure 2 Flow cytometry analysis of P-gp activity with Rh-123 in H22/ADM cells. A: Rh-123 fluorescence intensity curve in H22/ADM
cells after exposure to chemotherapeutic agents at 24 h. B: Rh-123 fluorescence intensity curve in H22/ADM cells after exposure to
chemotherapy agents at 48 h. C: Rh-123 fluorescence intensity curve in H22/ADM cells after exposure to chemotherapy agents at 72 h.
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ADM cells
After intervention for 24 h, 48 h, and 72 h, the levels of
MDR1 mRNA expression in H22/ADM cells were
detected by quantitative RT-PCR. As indicated in Table 3,
the levels of MDR1 mRNA expression decreased
(P < 0.05) in APS (APS 0.8 mg/L, APS 4 mg/L, APS
20 mg/L, APS 100 mg/L, APS 500 mg/L) and VER
groups compared to H22/ADM group at 24 h, 48 h, and
72 h time points; the levels of MDR1 mRNA expression
were higher in the RFP group than in the H22/ADM
group at 24 h, 48 h and 72 h. MDR1 mRNA expression
decreased with increasing concentrations of APS within
the range of 0.8–500 mg/L.
Existing data on the relationship between mRNA and
protein levels create a somewhat contradictory picture,
as shown in Figure 2 and Table 3. For example, there isno correlation between time dependent changes in the
MDR1 mRNA levels and corresponding P-GP levels.
This merits further study.
Discussion
The dried root of Astragalus membranaceus has a long
history of medicinal use in TCM. It is an adjunct antic-
ancer agent and it has been the subject of a great deal of
research [17,22,24]. Studies have shown that APS has
anti-tumor activity in vitro when applied alone in certain
tumor cell lines, such as murine renal cell carcinoma,
murine bladder tumors, HepG2 cells, human gastric
cancer SCG-7901 cells, human colon cancer cell lines,
hormone-sensitive (MCF-7) breast cancer cell lines, and
human hepatocellular carcinoma [13,17,24,25,29,30].
Animal tumor models and clinical studies have also con-
firmed that APS has anti-tumor activity [16,21-23,34].
Table 3 MDR1 mRNA expression in H22/ADM cells at
different times (24 h, 48 h, 72 h) (n = 6)
Group 2-44Ct (Mean± SD)
24 h 48 h 72 h
RFP 10 μmol/L 1.670± 0.027 1.977± 0.064 2.726± 0.086
H22/ADM 1.525± 0.039 1.797± 0.108 2.563± 0.048
VER 10 μmol/L 0.519± 0.045★ 0.497± 0.107▲ 0.440± 0.114●
APS 500 mg/L 0.616± 0.035★ 0.565± 0.033▲ 0.496± 0.072●
APS 100 mg/L 0.792± 0.163★ 0.742± 0.077▲ 0.898± 0.042●
APS 20 mg/L 0.890± 0.055★ 1.067± 0.107▲ 1.076± 0.108●
APS 4 mg/L 1.128± 0.051★ 1.183± 0.058▲ 1.412± 0.027●
APS 0.8 mg/L 1.260± 0.113★ 1.406± 0.024▲ 1.736± 0.063●
★ P< 0.05, vs. H22/ADM group (24 h); ▲P< 0.05, vs. H22/ADM group (48 h);
● P< 0.05, vs. H22/ADM group (72 h).
Table 2 Intracellular fluorescence intensity of Rh-123
accumulation in H22/ADM cells (n = 6)
Group Fluorescence intensity (mean± SD)
24 h 48 h 72 h
RFP 10 μmol/L 87.49 ± 1.26★ 133.71 ± 1.59▲ 131.41± 1.54
Control group 114.77± 1.16 198.51 ± 0.69 136.18± 1.32
APS 0.8 mg/L 135.52 ± 0.92★ 255.14 ± 0.61▲ 137.40± 2.01
APS 4 mg/L 257.38 ± 0.97★ 266.32 ± 2.03▲ 250.32 ± 1.80●
APS 20 mg/L 357.34 ± 0.80★ 285.75 ± 1.30▲ 367.35 ± 1.31●
APS 100 mg/L 342.83 ± 0.94★ 307.42 ± 1.12▲ 460.04 ± 1.74●
APS 500 mg/L 701.30 ± 1.14★ 345.27 ± 1.84▲ 458.43 ± 0.63●
VER 10 μmol/L 928.04 ± 1.17★ 706.04 ± 2.02▲ 657.91 ± 1.28●
★ P< 0.05, vs. Control group (24 h); ▲P< 0.05, vs. Control group (48 h);
● P< 0.05, vs. Control group (72 h).
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of drug-resistant tumor cells with APS. The present study
shows at a final concentration range of 0.8–500 mg/L, the
IC50 value of APS for H22/ADM cell proliferation was
251.77mg/L.According toNationalCancer Instituteguide-
lines,extractswithIC50values<20μg/mlareconsideredac-
tive in vitro [35]. The results show that thatAPShasno anti-
tumor activity for H22/ADM cells in vitro when applied
alone. However, patients with advanced cancer can be trea-
tedwithAPScombinedwithchemotherapeuticdrugs. Ithas
been found to inhibit tumor development, decrease the
toxic-adverse effects of chemotherapy, elevate immune
function, and improve patient quality of life [34-36]. For
example, Guo et al. reported that treatmentwithAPS injec-
tions integrated with vinorelbine and cisplatin significantly
improved quality of life in patients with advanced non-
small-cell lung cancer over vinorelbine and cisplatin alone
[23]. Animal tumor models and in vitro studies confirmed
that APS can enhance the chemo-sensitivity of the chemo-
therapy drugs for non-drug-resistant tumor cells [37-39].
For example, Li et al. reported that the weight of tumors in
subjects treatedwithAPS andADMwas significantly lowerFigure 3 P-GP expressions in H22/ADM cells after exposure to the dif
and 72 h).than those of the NS group [16]. Cui R. et al. reported that
hepatocarcinogenesiscouldbepreventedinrats fedwiththe
aqueous extract ofAstragalus,which ismainly composedof
Astragalus polysaccharides [21]. For H22/ADM resistant
cells, as shown in Figure 1 thatAPS combinedwithADMor
VCRcould significantly reduce the IC50 value (P < 0.05,VS.
control group) at APS concentration range of 4 mg/L to
500 mg/L; APS combined with 5-Fu, DDP, VP-16, or CTX
could significantly reduce the IC50 value (P < 0.05,VS. con-
trol group) atAPS concentration range of 0.8–500mg/L. In
thisway,APScanenhance thechemo-sensitivityof themost
common chemotherapy drugs in vitro. The present results
were partially supported by the results of the above-
mentionedstudies.
Those research teams speculated that the anti-tumor
activity of APS might involve enhancement of immune
function and induction of apoptosis. However, the mech-
anism underlying these effects remains to be determ-
ined. Changweiqing (Radix Astragali, Radix Codonopsis,
Rhizoma Atraety lodis macroce phalae) was found to re-
verse the drug resistance of colon cancer cells by redu-
cing the expression of MDR1/P-GP [25]. APS is theferent chemotherapy agents at different time points (24 h, 48 h,
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in the reversal of MDR merits further investigation
[13,14].
Drug resistance in tumor cells has been shown to be
related to MDR1 and P-GP overexpression [40-42]. In
the present study, APS was found to enhance the chemo-
sensitivity of H22/ADM cell lines to certain drugs. To
determine whether APS is involved in P-GP expres-
sion and/or its efflux function, the P-GP inducer RFP and
P-GP inhibitor VER were used as positive controls, and
an H22/ADM group was used as a blank control.
Rh-123 is a cationic dye. It has been used extensively
as a marker of P-GP-mediated transport in both in vitro
and in vivo studies [43-47]. In the present study, the
intracellular fluorescence intensity of Rh-123 increased
with increasing concentrations of APS in a concentration-
dependent manner in the range of 0.8–500 mg/L.
The results show that P-GP efflux activity was inhibited
by APS.
Western blot analysis of P-GP expression and quanti-
tative RT-PCR detection of MDR1 mRNA expression in
H22/ADM cell lines showed that APS reduced P-GP
protein expression and MDR1 mRNA expression in a
concentration-dependent manner within the range of
0.8–500 mg/L and in time-dependent manner from 24 h
to 72 h. APS not only inhibited P-GP efflux but also
reduced P-GP and MDR1 mRNA expression in a
concentration-dependent manner. However, this effect
was not uniform across all times. For example, APS
inhibition of P-GP efflux function did not occur in a
time-dependent manner; and there was no visible correl-
ation between time-dependent changes in the MDR1
mRNA levels and corresponding P-GP levels. The mod-
est correlation between mRNA expression and protein
abundance in large-scale data sets can be explained in
part by experimental challenges, such as technological
limitations, and in part by fundamental biological factors
in the transcription and translation processes. Transla-
tion is a complicated biological process, and many of the
details still merit further investigation. For example,
highly expressed proteins may not necessarily require
large quantities of mRNA if they have higher than aver-
age translation rates. This merits further study [48].
Drug resistance is a major obstacle to the successful
treatment of cancer. Tumor cells either fail to reduce in
size following chemotherapy or cancer recurs. The phe-
nomenon of MDR is particularly problematic because it
involves the simultaneous resistance to numerous che-
motherapeutics of different classes, and the mechanism by
which tumors develop MDR is very complex, P-GP over-
expression is one important factor in this process [49].
Studies have shown that APS has anti-tumor activity in
certain tumor cell lines in vitro and in animal models ofcertain tumors. The present study confirmed that
APS can downregulate MDR1 mRNA expression, inhibit
P-GP efflux function and decrease its expression, thereby
increasing the intracellular concentration of chemother-
apeutic drugs. This may be the mechanism behind its
secondary anti-cancer effects.
It has been reported that APS can increase the sensi-
tivity of chemotherapeutics, reducing the side effects
and complications associated with chemotherapy, and
improve patient quality of life and survival time
[12,14,19,20,23]. In this way, in the search for new can-
cer therapeutics with minimal toxicity and few side
effects, APS is a promising candidate.
Conclusion
In summary, APS was found to enhance the chemosen-
sitivity of the H22/ADM cell line, which may be related
to downregulation of MDR1 mRNA expression and
inhibition of P-GP efflux pump function, which decreases
its MDR1 protein expression.
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